Ictiobiotic Overview

  • Status
  • Private
  • Latest Deal Type
  • Accelerator/​Inc
  • Latest Deal Amount
  • $29.1K
Latest Deal Amount
  • Investors
  • 1

Ictiobiotic General Information


Developer of a proprietary oral bio-therapeutics platform intended to become a key supplier of oral bio-therapeutics that help reduce diseases and improve the sanitary status of fish farms. The company's platform express specific proteins to be used as immune-stimulants and vaccines, offers probiotics engineered to enhance fish immune system, oral vaccines to provide immunity against Piscirickettsia salmonis and Flavobacterium psychrophilum, enabling users to consume healthy and sustainable protein from aquaculture, free of antibiotics and other chemicals.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Other Industries
Other Pharmaceuticals and Biotechnology
Other Software
Primary Office
  • Gral. Del Canto 460
  • Providencia
  • Chile
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Ictiobiotic Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Accelerator/Incubator 20-Sep-2018 $29.1K 000.00 00000 Completed Startup
To view Ictiobiotic’s complete valuation and funding history, request access »

Ictiobiotic Executive Team (3)

Name Title Board Seat Contact Info
Francisco Ascui Co-Founder & Chief Executive Officer
Geraldine Mlynarz Co-Founder
Mario Tello Ph.D Co-Founder and Head Scientist
To view Ictiobiotic’s complete executive team members history, request access »

Ictiobiotic Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
HATCH (Consulting Services (B2B)) Accelerator/Incubator Minority 000 0000 000000 0
To view Ictiobiotic’s complete investors history, request access »